Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Medicago and GSK partner on COVID-19 vaccine trial  

By Brian Buntz | November 16, 2020

MedicagoThe Canadian biotech firm Medicago (CVE:MDG) is hooking up GlaxoSmithKline (NYSE:GSK) on a study involving 30,000 participants. 

The Quebec City-based Medicago had recently announced promising data concerning its plant-based vaccine candidate. 

Medicago’s vaccine is unique in that it uses virus-like particles that resemble the structure of the novel coronavirus but contain no genetic material from the virus. 

The phase 2/3 trial will investigate the safety and immune response of a combination of two doses of Medicago’s vaccine with GSK’s adjuvant. The two doses will be spaced 21 days apart. 

Medicago had recently announced that the plant-derived vaccine showed promising results in a Phase 1 study, which involved two doses of the vaccine candidate. 

The partially blinded study involved 180 volunteers between the ages of 18 and 55. 

Medicago’s vaccine candidate trails those such as Moderna and Pfizer, whose vaccine candidates promise to have an efficacy rate approaching 95% based on interim analyses of Phase 3 trials. Medicago’s product does have a potential advantage over the latter in terms of storage requirements. While Pfizer’s vaccine candidate must be held at –70° C, Medicago expects its vaccine to be stable at 2° to 8°C. Similarly, Moderna’s vaccine can be stored between 2° to 8°C for 30 days and for as long as six months when held at –20° C. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, GlaxoSmithKline, GSK, Medicago, Moderna, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50